In last trading session, Gritstone Bio Inc (NASDAQ:GRTS) saw 1.26 million shares changing hands with its beta currently measuring 0.40. Company’s recent per share price level of $2.73 trading at $0.02 or 0.74% at ring of the bell on the day assigns it a market valuation of $267.73M. That closing price of GRTS’s stock is at a discount of -21.98% from its 52-week high price of $3.33 and is indicating a premium of 58.24% from its 52-week low price of $1.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.5 million shares which gives us an average trading volume of 2.11 million if we extend that period to 3-months.
Gritstone Bio Inc (NASDAQ:GRTS) trade information
Upright in the green during last session for gaining 0.74%, in the last five days GRTS remained trading in the green while hitting it’s week-highest on Wednesday, 03/20/24 when the stock touched $2.73 price level, adding 0.36% to its value on the day. Gritstone Bio Inc’s shares saw a change of 33.82% in year-to-date performance and have moved 15.68% in past 5-day. Gritstone Bio Inc (NASDAQ:GRTS) showed a performance of 28.77% in past 30-days. Number of shares sold short was 8.22 million shares which calculate 4.32 days to cover the short interests.
Gritstone Bio Inc (GRTS) estimates and forecasts
Statistics highlight that Gritstone Bio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 97.83% of value to its shares in past 6 months, showing an annual growth rate of 20.83% while that of industry is 12.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -10.00% in the current quarter and calculating 3.20% increase in the next quarter. This year revenue growth is estimated to fall -7.30% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $920k for the same. And 5 analysts are in estimates of company making revenue of $920k in the next quarter that will end on Jun 2024. Company posted $2.44 million and $2.5 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -62.30% while estimating it to be -63.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 30.25% during past 5 years.
GRTS Dividends
Gritstone Bio Inc is more likely to be releasing its next quarterly report between May 09 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Gritstone Bio Inc (NASDAQ:GRTS)’s Major holders
Insiders are in possession of 2.48% of company’s total shares while institution are holding 43.60 percent of that, with stock having share float percentage of 44.71%. Investors also watch the number of corporate investors in a company very closely, which is 43.60% institutions for Gritstone Bio Inc that are currently holding shares of the company. Point72 Asset Management, L.P. is the top institutional holder at GRTS for having 7.57 million shares of worth $14.77 million. And as of Jun 29, 2023, it was holding 8.14% of the company’s outstanding shares.
The second largest institutional holder is Redmile Group, LLC, which was holding about 6.86 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.37% of outstanding shares, having a total worth of $13.38 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 2.49 million shares of worth $4.85 million or 2.67% of the total outstanding shares. The later fund manager was in possession of 1.96 million shares on Aug 30, 2023, making its stake of worth around $3.56 million in the company or a holder of 2.10% of company’s stock.
